Therapeutic Gain in Osteosarcoma Treatment with 211At-Labelled Antibody
Author Information
Author(s): R.H. Larsen, O.S. Bruland, P. Hoff, J. Alstad, E.K. Rofstad
Primary Institution: University of Oslo; The Norwegian Radium Hospital
Hypothesis
The study aims to measure and quantify the therapeutic gain from 211At-labelled monoclonal antibodies on antigen-positive versus antigen-negative microcolonies.
Conclusion
The study suggests that 211At-TP-3 may provide clinically favorable therapeutic ratios in the treatment of osteosarcoma.
Supporting Evidence
- Therapeutic gain factor values varied from 1.3 to 4.5.
- OHS cell line had higher therapeutic gain than KPDX.
- Significant differences in survival were observed based on colony size and treatment type.
Takeaway
This study looked at how well a special treatment using a radioactive antibody can help fight certain cancer cells compared to regular treatments.
Methodology
Microcolonies of human osteosarcoma and melanoma cell lines were treated with 211At-labelled monoclonal antibodies and X-rays, and survival was measured by colony formation.
Limitations
The study's in vitro conditions may not fully replicate the complex environment of tumors in patients.
Participant Demographics
The study involved human osteosarcoma cell lines (OHS and KPDX) and a melanoma cell line (WIX-c).
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website